ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MPH Mereo Biopharma Group Plc

26.50
0.00 (0.00%)
15 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Mereo Biopharma Group Plc LSE:MPH London Ordinary Share GB00BZ4G2K23 ORD GBP0.003 (REG S)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 26.50 26.00 27.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Mereo Biopharma Share Discussion Threads

Showing 8176 to 8195 of 8575 messages
Chat Pages: Latest  331  330  329  328  327  326  325  324  323  322  321  320  Older
DateSubjectAuthorDiscuss
15/4/2020
15:34
30k buyer in the stock...not sure how it's not moved yet
dave4545
15/4/2020
15:28
Nice buying today
leedslad001
14/4/2020
12:40
Topped up again today @22.40
leedslad001
11/4/2020
18:54
Cheers Leedslad
showmethemoneyhoney01
11/4/2020
15:33
I did speak to the CMO on Thursday about our COPD drug to see if that would be of use against c19. Works a different way to the virus c19Might be useful later down the track after recovery from c19.
leedslad001
11/4/2020
10:34
I wonder if there Alpha 1 lung disease MPH 966 could have any positive effects on treating lung disease caused by Covid 19. Extract from website below:-

Clinical Status
We have commenced a Phase 2, 12-week randomized, placebo-controlled, trial evaluating two doses of MPH-966 versus placebo that is expected to enroll approximately 165 patients with the PiZZ or NULL genetic mutations. The primary endpoint of the study is the change from baseline of desmosine/isodesmosine which are biomarkers of neutrophil elastase activity. Desmosine has been shown to correlate with deterioration of lung tissue as determined by CT scans in previous studies in AATD patients. Mereo expects to report top line data in mid-2020 and if the results are positive, will seek regulatory advice on the design of a pivotal trial. A total of 12 clinical studies have been completed to date in over 1,100 patients in a range of lung diseases demonstrating safety and good tolerability.

Would appreciate anyone's thoughts on this. NY Boy, could you run this past your industry contacts? I do hold some but with several projects ongoing, funding sorted, the market cap has struck me as low, even a few months ago when the share price rallied a bit.

showmethemoneyhoney01
11/4/2020
10:20
My medium term target is 50p, I know plenty of people in the industry who are aware of the potential of this Company but dyor as usual.
ny boy
11/4/2020
10:11
Interesting article from Jan 2020 on institutions owning MPH. Small extract below



What Does The Institutional Ownership Tell Us About Mereo BioPharma Group?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
Mereo BioPharma Group already has institutions on the share registry. Indeed, they own 60% of the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Mereo BioPharma Group, (below). Of course, keep in mind that there are other factors to consider, too.

showmethemoneyhoney01
09/4/2020
22:59
Too many unresearched on this thread.
showmethemoneyhoney01
09/4/2020
22:32
My bad missed the 10th Feb RNS..
ddonaldson2
09/4/2020
22:00
Better get in quick before you miss out there.Read the previous RNSss yourself.19 Feb - Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor10 Feb - Mereo BioPharma Secures Up to $33 Million Funding.
oapknob1
09/4/2020
21:55
Do your research already been done cash ready for Phase 3 trial
leedslad001
09/4/2020
20:46
Isn't there going to be a cash raise here soon? They are running out I through. Going to wait until that goes through if so.
ddonaldson2
09/4/2020
17:46
Mero CMO that was
leedslad001
09/4/2020
17:45
No drugs here to help c19 spoke to CMO today ref that
leedslad001
09/4/2020
15:51
Any links to c-19...that can drive a share nuts
dave4545
09/4/2020
13:16
We all know this well oversold. Loads cash in bank and lots of late stage drugs in pipeline.
leedslad001
09/4/2020
10:52
Agreed , I have substunial amount invested in MPH .good luck all.
dzygit1980
09/4/2020
10:45
Advisor and broker targets still need to be justified and I agree they can be quite optimistic but 30 fold. Anyway, I've been topping up down at these levels.
showmethemoneyhoney01
09/4/2020
10:39
I think this price forecast is given by Cantor Fitzgerald Europe and if you look on Mereo website Cantor Fitzgerald Europe is their advisor and broker.
dzygit1980
Chat Pages: Latest  331  330  329  328  327  326  325  324  323  322  321  320  Older